

<!--StartFragment-->

RESULT 14

AAW62772

ID AAW62772 standard; protein; 303 AA.

XX

AC AAW62772;

XX

DT 23-SEP-1998 (first entry)

XX

DE Human immunoglobulin receptor designated FDF03.

XX

KW Human; type I transmembrane protein; immunoglobulin-like domain; FDF03;

KW activated monocyte; YE01; KTE03; control; development; differentiation;

KW mammalian immune system; treatment; cancerous condition;

KW degenerative condition; autoimmune response; transplantation rejection;

KW graft versus host disease; inflammatory condition; detection; diagnosis;

KW drug screening.

XX

OS Homo sapiens.

XX

PN WO9824906-A2.

XX

PD 11-JUN-1998.

XX

PF 05-DEC-1997; 97WO-US021101.

XX

PR 06-DEC-1996; 96US-0032252P.

PR 09-DEC-1996; 96US-00762187.

PR 16-DEC-1996; 96US-0033181P.

PR 21-MAR-1997; 97US-0041279P.

XX

PA (SCHE ) SCHERING CORP.

XX

PI Adema GJ, Meyaard L, Gorman DM, Mcclanahan TK, Zurawski SM;

PI Zurawski G, Lanier LL, Phillips JH;

XX

DR WPI; 1998-333325/29.

DR N-PSDB; AAV38987.

XX

PT New isolated activated monocyte cell gene(s) - used to develop products

PT for treating e.g. cancer, degenerative conditions, autoimmune responses,

PT transplant rejection or inflammatory conditions.

XX

PS Claim 1; Page 60-61; 104pp; English.

XX

CC The present sequence represents a human protein, FDF03, which is a type I

CC transmembrane protein comprising an extracellular portion characterised

CC by immunoglobulin-like domains, indicating that the protein is a receptor

CC member of the immunoglobulin superfamily. The FDF03 gene is found in

CC activated monocytes. The specification also describes other proteins

CC encoded by activated monocytes, which are designated YE01 and KTE03. The

CC genes function in controlling development, differentiation, and/or

CC physiology of the mammalian immune system. The products can be used for

CC treating abnormal proliferation, regeneration, degeneration or atrophy.

CC They can be used for treating e.g. cancerous conditions, degenerative

CC conditions, autoimmune responses, transplantation rejection, graft versus

CC host disease, or inflammatory conditions. The products can also be used

CC for detection, diagnosis and drug screening

XX

SQ Sequence 303 AA;

Query Match 80.4%; Score 958; DB 2; Length 303;  
Best Local Similarity 80.8%; Pred. No. 3.6e-76;  
Matches 185; Conservative 15; Mismatches 19; Indels 10; Gaps 2;

```
Qy      1 MGRPLLLPLLLLQPPAFLQPGGSTGSGPSYLYGVTQPKHLSASMGGVEIPFSFYYPWE 60
          ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db      1 MGRPLLLPLLLPPAFLQPSGSTGSGPSYLYGVTQPKHLSASMGGVEIPFSFYYPWE 60

Qy     61 LAIVPNVRISWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQESGFLRISNLRKEDQ 120
          || |:||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db     61 LATAPDVRIWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQKSGFLRISNLQKQDQ 120

Qy    121 SVYFCRVELDTRSSGRQQQLQSIKGTCLTITQAVTT-----TTTWRPSSTTTIAGLRV 172
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db    121 SVYFCRVELDTRSSGRQQWQSIEGTKLSITQAVTTTTTQRPSSMTTTWRLSSTTTTGLRV 180

Qy    173 TESKGHSESWHLSLDTAIRVALAVAVLKTIVILGLLCLLLLWRRRKGSR 221
          |: | |:|||:||:|:|: ||:| | | :|||:| | | ||||| :
Db    181 TQKRRSDSWHISLETAVGVAVAVTVLGIMILGLICLLR--WRRRKGGQ 227
```

<!--EndFragment-->